JP2017531639A - シリル化ピリミジンプロドラッグ及びその使用方法 - Google Patents
シリル化ピリミジンプロドラッグ及びその使用方法 Download PDFInfo
- Publication number
- JP2017531639A JP2017531639A JP2017517661A JP2017517661A JP2017531639A JP 2017531639 A JP2017531639 A JP 2017531639A JP 2017517661 A JP2017517661 A JP 2017517661A JP 2017517661 A JP2017517661 A JP 2017517661A JP 2017531639 A JP2017531639 A JP 2017531639A
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- independently selected
- compound
- silylated
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 239000000651 prodrug Substances 0.000 title abstract description 67
- 229940002612 prodrug Drugs 0.000 title abstract description 67
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title abstract description 53
- 201000011510 cancer Diseases 0.000 claims abstract description 19
- 239000001257 hydrogen Substances 0.000 claims description 72
- 229910052739 hydrogen Inorganic materials 0.000 claims description 72
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 71
- 150000001875 compounds Chemical class 0.000 claims description 64
- 206010028980 Neoplasm Diseases 0.000 claims description 43
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- -1 pyrimidine compound Chemical class 0.000 claims description 25
- 150000003230 pyrimidines Chemical class 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 230000001225 therapeutic effect Effects 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 230000035699 permeability Effects 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010066476 Haematological malignancy Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 238000006884 silylation reaction Methods 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 27
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000002360 preparation method Methods 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 16
- GQGVBSHMRYHBTF-UOWFLXDJSA-N 4-amino-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 GQGVBSHMRYHBTF-UOWFLXDJSA-N 0.000 description 12
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 12
- 229960002756 azacitidine Drugs 0.000 description 11
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 10
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- BVSDIUUYQZNNRW-UOWFLXDJSA-N 6-amino-3-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 BVSDIUUYQZNNRW-UOWFLXDJSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229960003962 trifluridine Drugs 0.000 description 9
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 7
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 7
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 7
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 7
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 6
- MFEFTTYGMZOIKO-UHFFFAOYSA-N 5-azacytosine Chemical group NC1=NC=NC(=O)N1 MFEFTTYGMZOIKO-UHFFFAOYSA-N 0.000 description 6
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 6
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 229960005277 gemcitabine Drugs 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 0 *[C@]([C@](CO)O[C@]1N(C=CC=N2)C2=O)C1(F)F Chemical compound *[C@]([C@](CO)O[C@]1N(C=CC=N2)C2=O)C1(F)F 0.000 description 4
- YXSLMHOPYBUDME-TZLGMAPXSA-N 4-amino-1-[(2r,4s,5r)-4-benzoyl-3,3-difluoro-4-hydroxy-5-(1-hydroxy-2-oxo-2-phenylethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1C(F)(F)[C@@](O)(C(=O)C=2C=CC=CC=2)[C@@H](C(O)C(=O)C=2C=CC=CC=2)O1 YXSLMHOPYBUDME-TZLGMAPXSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- VCNVMGCFHZBMBU-ZGDXACBUSA-N C[Si]([C@@]1([C@@H](O[C@@H]([C@]1(O)[Si](C)(C)C)C(O)[Si](C)(C)C)N1C(=O)N=C(N)N=C1)O)(C)C Chemical compound C[Si]([C@@]1([C@@H](O[C@@H]([C@]1(O)[Si](C)(C)C)C(O)[Si](C)(C)C)N1C(=O)N=C(N)N=C1)O)(C)C VCNVMGCFHZBMBU-ZGDXACBUSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000007908 nanoemulsion Substances 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 125000004665 trialkylsilyl group Chemical group 0.000 description 3
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000028649 Ribonucleoside-diphosphate reductase Human genes 0.000 description 2
- 108010038105 Ribonucleoside-diphosphate reductase Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 125000002640 tocopherol group Chemical class 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical class CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- IAJINJSFYTZPEJ-UHFFFAOYSA-N 1h-pyrimidin-3-ium-2-one;chloride Chemical compound Cl.O=C1N=CC=CN1 IAJINJSFYTZPEJ-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- WSWQKUJOYCXTNX-DJSMDIAISA-N 4-amino-1-[(2S,3R,4R,5R)-2,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound F[C@H]1[C@@](O[C@@H]([C@H]1O)CO)(N1C(=O)N=C(N)N=C1)F WSWQKUJOYCXTNX-DJSMDIAISA-N 0.000 description 1
- RDZJLHBGYNBCPE-NTSWFWBYSA-N 4-amino-1-[(4s,5r)-4-hydroxy-5-(hydroxymethyl)-1,2-oxazolidin-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1N1O[C@H](CO)[C@@H](O)C1 RDZJLHBGYNBCPE-NTSWFWBYSA-N 0.000 description 1
- LMNPKIOZMGYQIU-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-pyrimidine-2,4-dione Chemical compound FC(F)(F)C1=CNC(=O)NC1=O LMNPKIOZMGYQIU-UHFFFAOYSA-N 0.000 description 1
- LAOLDMMWVYDDID-KVQBGUIXSA-N 6-amino-3-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 LAOLDMMWVYDDID-KVQBGUIXSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- DYKDDBLOMATDSD-AMXGMDGSSA-N C[Si](C)(C)[C@@]1(C([C@H](O)[C@@H](CO)O1)(F)F)N1C(=O)N=C(N)N=C1 Chemical compound C[Si](C)(C)[C@@]1(C([C@H](O)[C@@H](CO)O1)(F)F)N1C(=O)N=C(N)N=C1 DYKDDBLOMATDSD-AMXGMDGSSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-N Diphenyl phosphate Chemical class C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 102000001853 Pyrimidine Phosphorylases Human genes 0.000 description 1
- 108010054917 Pyrimidine Phosphorylases Proteins 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229910018557 Si O Inorganic materials 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 229940122020 Thymidine phosphorylase inhibitor Drugs 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- STORWMDPIHOSMF-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O STORWMDPIHOSMF-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Inorganic materials [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 150000003612 tocotrienol derivatives Chemical class 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- KYWVDGFGRYJLPE-UHFFFAOYSA-N trimethylazanium;acetate Chemical compound CN(C)C.CC(O)=O KYWVDGFGRYJLPE-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本願は、2014年10月8日に出願された米国特許出願No.62/061,526の利益を請求し、同出願はその全体において参照することにより明確に本書に組み込まれる。
本発明はシリル化ピリミジンプロドラッグ、シリル化ピリミジンプロドラッグを含む組成物、シリル化ピリミジンプロドラッグ及び組成物の製造方法、及びシリル化ピリミジンプロドラッグ及び組成物を用いたがんの治療方法を提供する。
ピリミジン誘導体は、効果的な化学療法薬として知られている。ゲムシタビン、変性糖と一緒のシチジンの類似体である2’,2’−ジフルオロデオキシリボースは、膵臓癌の治療のための単独治療として、そして非小細胞肺癌、乳癌及び卵巣癌の治療のための併用化学療法の一部として、最近認められた化学療法薬である(注射用ジェムザール(ゲムシタビンHCl)。2007年、エリリリーアンドカンパニー)。次の性質はゲムシタビンを有効な抗ガン剤とする。(1)それは、リボヌクレオシドジフォスフェートレダクターゼ(RR)の阻害剤であり、脱リン酸化リボヌクレオシドの脱リン酸化デオキシリボヌクレオシドへの転換を触媒する酵素である。(2)それはDNA鎖ターミネーターとして作用する。(3)それは、ピリミジンヌクレオシドホスホリラーゼの基質ではなく、従って、ヌクレオシドの別れたベース及び糖部分への分解を妨げる(Plunkett,W.ら;「ゲムシタビン:代謝、作用機構、及び自己増強」Semin. Oncol. 22(4;suppl 11):3−10,1995,Mini,E.ら「ゲムシタビンの細胞薬理学」Ann. Oncol. 17(Suppl 5)v7−v12,2006)。
本発明はシリル化ピリミジンプロドラッグである治療ドラッグ化合物、シリル化ピリミジンプロドラッグを含む組成物、シリル化ピリミジンプロドラッグの製造方法、及びシリル化ピリミジンプロドラッグ及び組成物を用いた癌の治療方法を提供する。
本発明は、シリル化ピリミジンプロドラッグである治療薬剤化合物と、シリル化ピリミジンプロドラッグを含む組成物と、シリル化ピリミジンプロドラッグおよび組成物を製造するための方法と、シリル化ピリミジンプロドラッグおよび組成物を使用して癌を処置するための方法とを提供する。
以下に限定されるものではないが、たとえば、大豆油、綿実油、菜種油、魚油、ヒマシ油、Capmul MCM、Captex 300、Miglyol 812、グリセリルモノオレエート、トリアセチン、アセチル化モノグリセリド、トリステアリン、ベヘン酸グリセリルおよびモノグリセリドのジアセチル酒石酸エステルなどのグリセリドを含む、合成してもあるいは天然の供給源に由来してもよい、モノ−、ジ−またはトリグリセリドを形成するためにグリセリンでエステル化された脂肪酸;
ポリエチレングリコールなどの他の部分に結合(共役結合)されたグリセリド(たとえば、Labrasol、Labrafac、Cremophor EL);
ジミリスチルホスファチジルコリン、卵レシチンおよびPEG化リン脂質などの天然あるいは合成のリン脂質;
脂肪アルコール(ミリスチン酸ミリスチル、パルミチン酸イソプロピル)または糖(ソルビタンモノオレエート、SPAN 80、Tween 80、ラウリン酸スクロース)を含む他の脂肪エステル;
ステアリルアルコール、ラウリルアルコール、ベンジルアルコールなどの脂肪アルコール、またはベンジルベンゾエートなどそのエステルもしくはエーテル;
脂溶性ビタミンおよび誘導体、たとえば、ビタミンE(トコフェロールおよびトコトリエノールと、トコフェロールおよびトコトリエノール誘導体、たとえばコハク酸ビタミンE、酢酸ビタミンEおよびコハク酸ビタミンEポリエチレングリコール(TPGS)などのすべてを含む)。
2’,2’−ジフルオロ−5−アザデオキシシチジンの調製
2’,2’−ジフルオロ−5−アザデオキシシチジン(化合物IV)の調製のために、スキームIに示される2つの選択的な経路が使用された。
ステップAにおけるように調製された3’,5’−ベンゾイル−2’,2’−ジフルオロ−5−アザデオキシシチジン(化合物III)(15mg,α及びβ異性体の3:1混合物)は2mlの無水MeOHに溶解され、MeOH(0.1ml)中の1M NaOMeが添加された。室温で1時間後、反応混合物は蒸発され、保護解除された異性体はGemini C18 5u(21.2×250mmカラム)のRP HPLC(高速液体クロマトグラフィー)により50mMの酢酸トリエチルアンモニウム(pH7.5)−アセトニリトル溶離液で分離された。分離後、直ちに、β−異性体に相当するフラクションがプールされ、10℃未満で蒸発され、0.4mg(19%)の2’,2’−ジフルオロ−5−アザデオキシシチジン(化合物IV)が生成した。
工程A(3)に説明されるように調製されたシリル化5−アザシトシン(2.3g、9ミリモル)は2mlのアニソールに130℃で溶解された。Chouら,「Synthesis」1992,565−570頁に説明されるように調製された1−メチルスルホニル−2−デオキシ−2,2−ジフルオロ−D−リボフラノシル−3,5−ジベンゾエート(化合物II)(0.4g、0.87ミリモル)は、1mlのアニソールに溶解され、シリル化5−アザシトシンの熱い溶液に添加された。反応混合物は、150℃で7時間インキュベートされ、室温に冷却され、15mlの塩化メチレン、15gのシリカゲル及び5mlのメタノールが添加されて反応停止され、懸濁液は真空乾燥された。得られた粉末は、パックされたシリカゲルカラムの上部に供給され、クロロホルム−メタノール溶離液によるフラッシュクロマトグラフィーによって単離された。適当なフラクションはプールされ、蒸発され、α−及びβ−異性体の2:1混合物(100mg,25%収率)として3’,5’−ジベンゾイル−2’,2’−ジフルオロ−5−アザデオキシシチジン(化合物III)を生じた。
工程Cにおけるようにして調製された、3’,5’−ジベンゾイル−2’,2’−ジフルオロ−5−アザデオキシシチジン(化合物III)(80mg,α及びβ異性体の2:1混合物)が2mlの無水メタノールに溶解され、MeOH(0.1ml)中の1M NaOMeが添加された。室温で1時間後、反応混合物は蒸発され、保護解除された異性体はGemini C18 5u(21.2×250mmカラム)のRP HPLCにより50mMの酢酸トリエチルアンモニウム(pH7.5)−アセトニリトル溶離液で単離された。分離後、直ちに、β異性体に相当するフラクションがプールされ、10℃未満で蒸発され、2.1mg(13%)の2’,2’−ジフルオロ−5−アザデオキシシチジン(化合物IV)が生成した。
2’,2’−ジフルオロ−5,6−ジヒドロ−5−アザデオキシシチジンの製造
2’,2’−ジフルオロ−5,6−ジヒドロ−5−アザデオキシシチジン(化合物VI)の製造はスキーム2に示されている。
実施例1のようにして製造された3’,5’−ジベンゾイル−2’,2’−ジフルオロ−5−アザデオキシシチジン(化合物III)の純粋なβ−異性体(144mg,0.30ミリモル)が3mlの塩化メチレンに溶解され、トリエチルアミン(0.12ml)及びクロロトリメチルシラン(0.1ml)が添加された。0.5時間後、反応混合物は5ml酢酸で希釈され、ナトリウムボロハイドライド(100mg、2.6ミリモル)が粉末として添加された。室温で1時間後、反応混合物は蒸発され、Gemini C18 5u(21.2×250mmカラム)のRP HPLCにより50mMの酢酸トリエチルアンモニウム(pH7.5)−アセトニリトル溶離液で分離された。生成物に相当するフラクションがプールされ、蒸発され、83mg(57%)の3’,5’−ジベンゾイル−2’,2’−ジフルオロ−5−アザデオキシシチジン(化合物V)が生成した。
工程Aのようにして製造された3’,5’−ジベンゾイル−2’,2’−ジフルオロ−5−アザデオキシシチジン(化合物V)(80mg、0.168ミリモル)が6mlの無水MeOHに溶解され、MeOH(0.3ml)中の1M NaOMeが添加された。室温で1時間後、反応混合物は酢酸(0.02ml)が添加されて反応停止され、蒸発され、保護解除された生成物は、Gemini C18 5u(21.2×250mmカラム)のRP HPLCにより50mMの酢酸トリエチルアンモニウム(pH7.5)−アセトニリトル溶離液で単離された。適当なフラクションがプールされ、蒸発され、49mg(95%収率)の2’,2’−ジフルオロ−5,6−ジヒドロ−5−アザデオキシシチジン(化合物VI)が生成した。
2’,2’−ジフルオロゼブラリンの製造
2’,2’−ジフルオロデオキシリボース−トリフルオロチミジンの製造
代表的なシリル化ピリミジンプロドラッグの製造
代表的シリル化ピリミジンプロドラッグ:
2’,3’,5’−トリ(トリメチルシリル)−5−アザシチジン(NUC025)
Claims (32)
- R1及びR2がSi(R4)(R5)(R6)であり、R4,R5及びR6がメチルである請求項1〜3のいずれかの化合物。
- R1,R2及びR3がSi(R4)(R5)(R6)であり、R4,R5及びR6がメチルである請求項6〜8のいずれかの化合物。
- R1及びR2がSi(R4)(R5)(R6)であり、R4,R5及びR6がメチルである請求項11〜13のいずれかの化合物。
- R1及びR2がSi(R4)(R5)(R6)であり、R4,R5及びR6がメチルである請求項16の化合物。
- R1及びR2がSi(R4)(R5)(R6)であり、R4,R5及びR6がメチルである請求項16の化合物。
- 請求項1〜19のいずれかのシリル化ピリミジン化合物と薬学的に許容可能な担体とを含む薬剤組成物。
- 請求項20の薬剤組成物の有効量をこれを必要とする対象に投与することを含む、改良された浸透性及び保持性による腫瘍部位への治療ピリミジン化合物のデリバリー方法。
- 請求項20の薬剤組成物の有効量をこれを必要とする対象に投与することを含む、癌の治療方法。
- 請求項20の薬剤組成物の治療的に有効量をこれを必要とする対象に投与する、固形がん腫瘍の治療方法。
- シリル化治療用ピリミジン化合物。
- 請求項24のシリル化治療用ピリミジン化合物と薬学的に許容可能な担体とを含む薬剤組成物。
- 請求項25の薬剤組成物の有効量をこれを必要とする対象に投与する、改良された浸透性及び保持性による腫瘍部位への治療ピリミジン化合物のデリバリー方法。
- 請求項25の薬剤組成物の有効量をこれを必要とする対象に投与することを含む、癌の治療方法。
- 請求項25の薬剤組成物の治療的に有効量をこれを必要とする対象に投与する、固形がん腫瘍の治療方法。
- 固形がん腫瘍が、乳がん、非小細胞肺がん及び結腸がんから選ばれる請求項28の方法。
- 請求項25の薬剤組成物の有効量をこれを必要とする対象に投与することを含む、血液悪性腫瘍の治療方法。
- 血液悪性腫瘍が白血病である請求項30の方法。
- 対象が人間である、請求項26〜31のいずれか一つの方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462061526P | 2014-10-08 | 2014-10-08 | |
US62/061,526 | 2014-10-08 | ||
PCT/US2015/054755 WO2016057828A1 (en) | 2014-10-08 | 2015-10-08 | Silylated pyrimidine prodrugs and methods of their use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017531639A true JP2017531639A (ja) | 2017-10-26 |
JP6724909B2 JP6724909B2 (ja) | 2020-07-15 |
Family
ID=55653798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017517661A Active JP6724909B2 (ja) | 2014-10-08 | 2015-10-08 | シリル化ピリミジンプロドラッグ及びその使用方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10479807B2 (ja) |
EP (1) | EP3204121B1 (ja) |
JP (1) | JP6724909B2 (ja) |
CA (1) | CA2963686A1 (ja) |
ES (1) | ES2746105T3 (ja) |
WO (1) | WO2016057828A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019160127A1 (ja) * | 2018-02-19 | 2019-08-22 | 大原薬品工業株式会社 | Dnmt阻害剤の用途 |
JPWO2021060341A1 (ja) * | 2019-09-26 | 2021-04-01 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019506434A (ja) * | 2016-02-26 | 2019-03-07 | エピジェネティクス・ファーマ・エルエルシー | 2’,2’−ジフルオロ−5−アザ−2’−デオキシシチジンまたはそれらのプロドラッグを有するtp53野生型腫瘍の治療方法 |
JP6162349B1 (ja) | 2016-04-21 | 2017-07-12 | 大原薬品工業株式会社 | 5−アザシチジン類の糖部シリルエーテル誘導体 |
WO2017183215A1 (ja) * | 2016-04-21 | 2017-10-26 | 大原薬品工業株式会社 | 5-アザシチジン類の糖部シリルエーテル誘導体 |
US10227374B2 (en) | 2016-04-21 | 2019-03-12 | Ohara Pharmaceutical Co., Ltd. | Silyl etherified derivatives of 5-azacytidines in carbohydrate moiety |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR920002143B1 (ko) * | 1988-07-11 | 1992-03-12 | 다이호 야꾸힝고오교 가부시끼가이샤 | 5-치환 우리딘 유도체 및 그의 제조 중간체 |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US6413945B1 (en) | 1997-04-04 | 2002-07-02 | Pharmacia Corporation | Gastro-specific prodrugs |
CA2331386A1 (en) | 1998-06-26 | 2000-01-06 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
GB0227906D0 (en) | 2002-11-29 | 2003-01-08 | Amedis Pharm Ltd | Compounds and their use |
AU2003302624A1 (en) | 2002-11-29 | 2004-06-23 | Amedis Pharmaceuticals Ltd. | Silicon compounds |
US20080261918A1 (en) * | 2004-12-17 | 2008-10-23 | Graham Andrew Showell | Silicon Compounds and Their Use |
WO2006070985A1 (en) | 2004-12-30 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | METHOD FOR THE PREPARATION OF 2#-DEOXY-2#,2#-DIFLUOROCYTIDINE |
US7250416B2 (en) * | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
EP2321302B1 (en) | 2008-08-01 | 2014-10-29 | Dr. Reddy's Laboratories Ltd. | Azacitidine process and polymorphs |
UA117095C2 (uk) | 2011-12-22 | 2018-06-25 | Аліос Біофарма, Інк. | Нуклеозидна сполука або її фармацевтично прийнятна сіль |
-
2015
- 2015-10-08 EP EP15849800.6A patent/EP3204121B1/en active Active
- 2015-10-08 JP JP2017517661A patent/JP6724909B2/ja active Active
- 2015-10-08 WO PCT/US2015/054755 patent/WO2016057828A1/en active Application Filing
- 2015-10-08 US US15/516,653 patent/US10479807B2/en active Active
- 2015-10-08 ES ES15849800T patent/ES2746105T3/es active Active
- 2015-10-08 CA CA2963686A patent/CA2963686A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019160127A1 (ja) * | 2018-02-19 | 2019-08-22 | 大原薬品工業株式会社 | Dnmt阻害剤の用途 |
JPWO2019160127A1 (ja) * | 2018-02-19 | 2021-04-22 | 大原薬品工業株式会社 | Dnmt阻害剤の用途 |
JPWO2021060341A1 (ja) * | 2019-09-26 | 2021-04-01 | ||
WO2021060341A1 (ja) * | 2019-09-26 | 2021-04-01 | 大原薬品工業株式会社 | Dnmt阻害剤の用途 |
Also Published As
Publication number | Publication date |
---|---|
JP6724909B2 (ja) | 2020-07-15 |
EP3204121B1 (en) | 2019-06-19 |
EP3204121A4 (en) | 2018-05-09 |
CA2963686A1 (en) | 2016-04-14 |
EP3204121A1 (en) | 2017-08-16 |
WO2016057828A1 (en) | 2016-04-14 |
ES2746105T3 (es) | 2020-03-04 |
US20170305941A1 (en) | 2017-10-26 |
US10479807B2 (en) | 2019-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6724909B2 (ja) | シリル化ピリミジンプロドラッグ及びその使用方法 | |
US6815542B2 (en) | Nucleoside compounds and uses thereof | |
JP6769000B2 (ja) | 4’−チオヌクレオシドの新規な化合物、並びにその調製方法、その医薬組成物及びその用途 | |
JP5087052B2 (ja) | 改良された治療剤 | |
WO2001068663A1 (en) | Nucleoside compounds and uses thereof | |
JP2010540555A (ja) | アザシチジン類似体およびその使用 | |
EP3252067B1 (en) | Sugar moiety silyl ether derivative of 5-azacytidine | |
KR101869940B1 (ko) | 암 치료를 위한 제불라린 또는 1'-시아노-시타라빈 및 단쇄 지방산을 포함하는 상호 전구약물 | |
US10071112B2 (en) | Vitamin E-nucleoside prodrugs | |
ES2877103T3 (es) | Análogos de pirimidina fluorados y métodos de uso de los mismos | |
CN106928298B (zh) | 环二核苷酸cGAMP衍生物的结构组成、制备方法及其在抗肿瘤中的应用 | |
WO2018230479A1 (ja) | ヌクレオシド系抗がん剤又は抗ウィルス剤の5'位シリルエーテル誘導体 | |
US9493500B2 (en) | Fluorinated pyrimidine analogs and methods of use thereof | |
JP2019506434A (ja) | 2’,2’−ジフルオロ−5−アザ−2’−デオキシシチジンまたはそれらのプロドラッグを有するtp53野生型腫瘍の治療方法 | |
RU2471486C2 (ru) | Противоопухолевое средство для непрерывного внутривенного введения, содержащее цитидиновое производное | |
RU2487883C2 (ru) | Аналоги азацитидина и их применение | |
CN104619325A (zh) | 治疗肿瘤的组合药物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180921 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190523 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190528 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190826 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200130 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200421 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200526 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200608 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6724909 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |